-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 12, Shanghai Kasai Biotechnology Co.
, Ltd.
(hereinafter referred to as "Kasai Bio"), a company focusing on new bio-based materials, was officially listed on the Shanghai Stock Exchange's Science and Technology Innovation Board with the stock code of 688065
.
According to the prospectus of Kasai Biological, the company is a high-tech enterprise engaged in the research and development, production and sales of new bio-based materials based on synthetic biology and other disciplines, using bio-manufacturing technology
.
Source: Cathay Bioprospectus
According to the prospectus, from 2017 to 2019, the main business income of Kasai Bio was 1.
363 billion yuan, 1.
757 billion yuan, and 1.
916 billion yuan respectively; the net profit after deducting non-return to the parent was 312 million yuan, 434 million yuan, and 461 million yuan respectively.
.
2017-2019 Company revenue and net profit after deduction
The business layout plays a radiating role, and has established long-term cooperative relations with DuPont, Evonik, etc.
Established long-term cooperative relations with DuPont and Evonik.
According to the prospectus, Kasai Bio's production capacity is currently mainly concentrated in Shandong and Xinjiang, which have the advantages of abundant raw materials, energy and other resources and low prices
.
The geographical layout of Kasai Bio's business has played a very good role in radiation, making the company closer to domestic and foreign customers and markets, thereby improving the company's ability to expand customers and serve customers
.
The prospectus shows that Kasai Bio is currently the world's representative leading enterprise that can realize the biological production of a series of long-chain dibasic acids and large-scale industrialization.
, established a good brand image in the market, established long-term and stable business cooperation with well-known enterprises such as DuPont, Emmans, Novo Nordisk, Evonik, etc.
, and cooperated with downstream customers to deeply develop product potential applications to further enhance customer stickiness
.
The quality and performance of the biological long-chain dibasic acid is outstanding, and it was awarded the single champion product of the manufacturing industry by the Ministry of Industry and Information Technology.
It was awarded the single champion product of the Ministry of Industry and Information Technology.
According to the prospectus, the products currently commercialized by Cathay Biotech mainly focus on the polyamide industry chain, which are bio-based polyamides and raw materials that can be used for bio-based polyamide production, including DC12 (lauric acid), DC13 (Brazilian acid) It is one of the world's leading enterprises that use biological manufacturing to produce new materials on a large scale
.
Source: Cathay Bioprospectus
1.
Biological long-chain dibasic acid series products
In recent years, the long-chain dibasic acid products of Cathay Biotechnology have been continuously expanding the downstream application fields.
At present, high-performance long-chain polyamides, fragrances, high-grade hot melt adhesives, high-grade lubricating oils, cold-resistant plasticizers, powder coatings and other downstream products have been formed.
application market
.
2.
Bio-based pentamethylenediamine
Polyamide products can be produced by polycondensation of dibasic acid and diamine or by ring-opening polymerization of lactam.
One of the main products, polyamide 66, is produced by the polymerization of hexamethylene diamine and adipic acid.
The dinitrile market has been dominated by European and American manufacturers for a long time.
Cathay Biotech independently produces bio-based pentamethylene diamine by means of biological manufacturing methods, and achieves a technological breakthrough in the production of diamines.
While it is expected to solve the main bottleneck in the development of the domestic polyamide industry, it will provide market, Customers provide new "bio-manufactured" new materials derived from renewable biomass feedstocks
.
3.
Bio-based polyamide
Relying on polyamide 56 products, Kasai Bio has created its own textile material "Tylon", which has certain advantages in flame retardancy, moisture absorption and perspiration, dyeing ability, etc.
All have the potential to replace traditional nylon chemical fibers and other raw materials
.
"Tailun" was also selected as the "Most Concerned Fiber Product" at the 2017 China International Textile Yarn (Spring and Summer) Exhibition, and was selected as "China Fiber Trend" for two consecutive years
.
Kasai Bio said that the company's current development direction mainly focuses on the polyamide industry chain.
Bio-based polyamide and its monomer bio-based pentamethylene diamine products are an important part of the polyamide industry chain.
The issuer's important research products and investment and construction directions are the company's important reserve products
.
At present, the large-scale production line of bio-based polyamide and its monomer bio-based pentamethylene diamine in the issuer's Wusu plant is undergoing equipment commissioning
.
